TIPCO GROUP combines technology, expertise, and scientific insight to transform healthcare delivery. Our holistic approach is designed to improve clinical outcomes and optimize the experience for healthcare providers and patients alike.
BioStem Technologies has finished enrolling 71 patients in a clinical trial evaluating its amnion-chorion placental allograft (BioRETAIN) for diabetic foot ulcers (DFUs); topline data are expected in Q4 2025.
On June 23, 2025, BioStem reported complete enrollment in a multicenter study testing BioRETAIN—an amnion-chorion placental allograft—for the treatment of diabetic foot ulcers. The trial’s completion of enrollment marks a key milestone toward generating prospective data on healing outcomes, safety, and potential cost-effectiveness compared with standard care. The company anticipates topline results in late 2025, which could inform payer decisions and clinical adoption in outpatient wound-care settings.
Let's Build Healthier Solutions Together
Get in touch with our team to discuss your healthcare needs